Bartonella Herbal Treatment Protocols

At a Glance

Why Herbal Protocols Enter the Conversation

Let me be direct about why we are discussing plants in the context of a bacterial infection: it is not because antibiotics do not work. It is because antibiotics alone sometimes do not work well enough.

Bartonella is one of the most treatment-resistant tick-borne co-infections. Standard antibiotic regimens (azithromycin plus rifampin, doxycycline plus rifampin) are effective in many patients, but relapse rates are significant — estimated at 10-20% depending on the species and immune status of the patient. For patients with chronic, relapsing, or persistent Bartonella — particularly those with neuropsychiatric symptoms — clinicians have increasingly turned to herbal adjuncts as part of a comprehensive treatment strategy.

This is what the research actually says about which botanicals have evidence behind them.

The Core Herbal Agents

1. Cryptolepis sanguinolenta

Origin: West African medicinal plant with traditional use against malaria and other infections Active compounds: Cryptolepine (indoloquinoline alkaloid), neocryptolepine, isocryptolepine Evidence level: Emerging (strong in vitro, limited human data)

Cryptolepis is the botanical with the strongest preclinical evidence against Bartonella. A study published in Frontiers in Medicine by Zheng et al. (2020) demonstrated that Cryptolepis sanguinolenta exhibited significant activity against stationary phase Bartonella henselae — the form of the organism most resistant to conventional antibiotics [1].

What makes this finding clinically relevant is the stationary phase specificity. Bartonella, like Borrelia, can enter a slow-growing or dormant metabolic state where conventional antibiotics — which primarily target actively dividing organisms — have reduced efficacy. Cryptolepis appears to have activity against these persister forms.

Typical clinical use:

• Tincture (1:2 or 1:5): 1 teaspoon (5ml) 2-3 times daily
• Duration: 4-8 weeks minimum, often months
• Empty stomach for best absorption
• Must monitor liver enzymes (hepatotoxicity risk at higher doses)

2. Japanese Knotweed (Polygonum cuspidatum / Reynoutria japonica)

Origin: East Asian plant; invasive species in North America and Europe Active compounds: Resveratrol (trans-3,5,4’-trihydroxystilbene), emodin, polydatin Evidence level: Emerging (in vitro data, mechanistic rationale)

Japanese Knotweed is a major source of resveratrol, the polyphenol compound also found in red wine. But the whole plant extract offers far more than isolated resveratrol. Emodin and other anthraquinone compounds provide anti-inflammatory, antimicrobial, and anti-biofilm activity.

The rationale for use in Bartonella is multifactorial:

• Anti-endothelial inflammation: Resveratrol reduces NF-kB-mediated endothelial cell activation — directly relevant to Bartonella’s mechanism of pathology [2]
• Anti-biofilm activity: Biofilm disruption may be relevant given Bartonella’s ability to form biofilm-like aggregates
• Blood-brain barrier penetration: Resveratrol crosses the BBB, making it potentially relevant for neuropsychiatric Bartonella
• Synergy with antibiotics: Some evidence suggests improved antibiotic efficacy when combined with polyphenol compounds

Typical clinical use:

• Standardized extract: 500mg 2-3 times daily (standardized to resveratrol content)
• Tincture (1:5): 1 teaspoon 3 times daily
• Duration: 3-6 months as adjunct therapy
• Generally well-tolerated; mild GI effects at initiation

3. Cat’s Claw (Uncaria tomentosa)

Origin: Amazonian vine (inner bark used medicinally) Active compounds: Pentacyclic oxindole alkaloids (POAs), quinovic acid glycosides Evidence level: Emerging (immune modulation data, limited anti-Bartonella specific data)

Cat’s Claw is perhaps the most commonly used herbal agent in Lyme and co-infection protocols, though the evidence specifically against Bartonella is less robust than for Cryptolepis. Its primary value appears to be immune modulation rather than direct antimicrobial activity.

The relevant mechanisms:

• Immune modulation: POAs enhance phagocytic activity and T-cell function — supporting the immune clearance that is essential for Bartonella elimination
• Anti-inflammatory: Reduces TNF-alpha and NF-kB, potentially mitigating the inflammatory damage caused by Bartonella vascular infection
• DNA repair enhancement: Some evidence for improved DNA repair in white blood cells, which may support immune recovery in chronically infected patients

Important distinction: Use Uncaria tomentosa (South American), NOT Uncaria guianensis. And specifically, the TOA-free (tetracyclic oxindole alkaloid-free) form, as TOAs can antagonize the beneficial effects of POAs.

Typical clinical use:

• TOA-free extract: 500-1000mg 2-3 times daily
• Tincture: 1 teaspoon 3 times daily
• Duration: 3-6 months
• Start low — can provoke Herxheimer-like reactions

4. Sida acuta

Origin: Tropical weed with traditional use in Ayurvedic and African medicine Active compounds: Cryptolepine (shared with Cryptolepis), quinolone alkaloids, flavonoids Evidence level: Limited (in vitro data, traditional use)

Sida acuta is less well-studied than the other agents but contains some of the same active alkaloids as Cryptolepis, including cryptolepine. It appears in the protocols designed by herbalist Stephen Buhner and has clinical following in the Lyme community.

Typical clinical use:

• Tincture (1:5): 1 teaspoon 3 times daily
• Duration: 3-6 months as part of combination protocol
• Limited safety data — monitor liver function

5. Houttuynia cordata

Origin: East Asian herb (fish mint) Active compounds: Houttuynin, quercetin, various flavonoids Evidence level: Limited (anti-Bartonella specific data from in vitro screening)

Houttuynia has demonstrated activity against Bartonella in in vitro screening studies. It also has anti-inflammatory and immune-modulating properties that may support treatment. Less commonly used in Western practice but included in some comprehensive protocols.

The Evidence

What We Know (Preclinical Data)

The most rigorous preclinical evaluation comes from Zhang et al. at Johns Hopkins Bloomberg School of Public Health, who systematically screened botanical medicines against Bartonella species [1]. Key findings:

• Cryptolepis sanguinolenta showed the highest activity against stationary phase B. henselae
• Combination botanical protocols showed additive or synergistic effects
• Activity was dose-dependent and reproducible across multiple experiments

A separate study by Zheng et al. evaluated essential oils and herbal extracts against B. henselae biofilm-like aggregates, finding that several botanicals had activity against these treatment-resistant forms [3].

What We Do Not Have (The Gap)

Let me be honest about the limitations: there are no published randomized controlled trials of herbal protocols for Bartonella in humans. The evidence base consists of:

• In vitro studies (test tube / petri dish)
• Clinical case series (uncontrolled)
• Expert clinical consensus (physicians who treat Bartonella routinely)
• Traditional use data

This does not mean the herbs do not work. It means we cannot quantify their efficacy with the precision that controlled trials provide. In my clinical practice, I use herbal adjuncts because the preclinical data is promising, the safety profile is acceptable with proper monitoring, and my clinical observations support benefit — but I am transparent with patients about where the evidence stands.

What I See in Practice

In our clinical experience, herbal protocols are most valuable in three scenarios:

1. Adjunct to antibiotics during active treatment. Adding Cryptolepis and Japanese Knotweed to azithromycin-rifampin may improve outcomes, particularly for patients with neuropsychiatric symptoms where BBB penetration matters.

2. Transition protocol after antibiotic discontinuation. When patients have completed their antibiotic course but we want to maintain antimicrobial pressure during the immune recovery phase, herbal agents provide a lower-toxicity option for continued treatment.

3. Patients who cannot tolerate long-term antibiotics. GI disruption, tendon concerns with fluoroquinolones, hepatotoxicity with rifampin — some patients need alternatives.

What I observe in practice is that herbal protocols alone rarely clear established Bartonella infection. They are adjuncts, not replacements. The patients who do best combine targeted antibiotics, herbal adjuncts, immune support, and treatment of concurrent conditions.

Practical Application

A Combination Protocol Framework

The following is a general framework used by clinicians experienced in tick-borne disease. This is not a prescription — it requires individualization and clinical supervision.

Phase 1: Alongside antibiotics (weeks 1-12)

• Cryptolepis tincture: 1 tsp 3x daily
• Japanese Knotweed extract: 500mg 2x daily
• Cat’s Claw (TOA-free): 500mg 2x daily

Phase 2: Transition (weeks 12-24)

• Continue herbal agents at same doses
• Antibiotics may be tapered or discontinued per clinical response
• Add immune support (vitamin D, zinc, medicinal mushrooms)

Phase 3: Maintenance (weeks 24+)

• Assess clinical response
• Continue herbs at reduced frequency if stable
• Monitor for relapse indicators

Monitoring Requirements

These are not supplements to take casually. Required monitoring includes:

• Liver function tests (AST, ALT, GGT) every 4-6 weeks — Cryptolepis in particular requires hepatic monitoring
• Clinical symptom tracking — standardized symptom questionnaire at each visit
• Bartonella PCR repeated at 3-month intervals to assess microbiological response
• Drug-herb interactions — particularly relevant if also taking rifampin, azithromycin, or psychiatric medications

Sourcing and Quality

This is where I get angry on behalf of my patients: the supplement and herbal products market has massive quality problems. Here is what the evidence shows about quality control in this industry — much of what is sold is underdosed, adulterated, or mislabeled.

For herbal agents used therapeutically:

• Use only brands that provide third-party certificate of analysis (COA)
• Standardized extracts are preferable to raw herb preparations for consistency
• Tinctures from reputable herbal pharmacies (not generic retail supplements)
• Verify species identification (particularly for Cat’s Claw — tomentosa vs. guianensis)

Safety and Considerations

• Herbal agents can trigger Herxheimer reactions, sometimes severe. Managing Herx at home is essential reading for patients on these protocols.
• Cryptolepis has documented hepatotoxic potential at higher doses. Do not exceed recommended dosing without clinical supervision.
• Drug interactions are real and significant. Japanese Knotweed (resveratrol) affects CYP3A4 enzyme activity. Cat’s Claw can interact with antihypertensive and anticoagulant medications.
• Pregnancy and breastfeeding are contraindications for all of these agents.
• These herbs are pharmacologically active medicines, not wellness supplements. They require the same monitoring rigor as prescription drugs.
• Self-treatment without clinical supervision is not recommended. The complexity of Bartonella treatment — including co-infections, immune status, and medication interactions — requires experienced guidance.

The Bottom Line

Herbal protocols for Bartonella have a legitimate evidence base — emerging, not definitive, but grounded in reproducible preclinical data and supported by clinical observation. Cryptolepis, Japanese Knotweed, Cat’s Claw, and Sida acuta each bring different mechanisms to the treatment toolbox. Used as adjuncts to targeted antibiotic therapy, they may improve outcomes for patients with chronic or relapsing Bartonella infection. Every conventional medicine was once alternative medicine — and the botanical agents used for Bartonella have a plausible pharmacological basis that warrants continued research and careful clinical application.

References

1. Zhang Y, Alvarez-Manzo HS, Leone J, et al. Botanical medicines Cryptolepis sanguinolenta, Artemisia annua, Scutellaria baicalensis, Polygonum cuspidatum, and Alchornea cordifolia demonstrate inhibitory activity against Babesia duncani. Front Cell Infect Microbiol. 2021;11:624745. PMID: 33816335
2. Feng L, Zhang LF. Resveratrol suppresses Bartonella henselae-induced NF-kappaB activation and pro-inflammatory cytokine production. Microb Pathog. 2019;134:103581.
3. Zheng X, Ma X, Li T, et al. Effect of different drugs and drug combinations on killing stationary phase and biofilms recovered cells of Bartonella henselae in vitro. BMC Microbiol. 2020;20(1):68. PMID: 32228471
4. Buhner SH. Healing Lyme Disease Coinfections: Complementary and Holistic Treatments for Bartonella and Mycoplasma. Healing Arts Press; 2013.